Literature DB >> 29759124

The Seronegative Spondyloarthropathies.

Ayyappa S Duba1, Stephanie D Mathew2.   

Abstract

The seronegative spondyloarthropathies are a group of five diseases characterized by inflammatory oligoarticular arthritis, enthesitis, and axial involvement. They have an increased incidence of the HLA-B27 gene. They are commonly associated with extra-articular features including involvement of the skin, eyes, and gastrointestinal tract. Early recognition and referral are key to limit disability, and comanagement with primary care and rheumatology offers the best outcomes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ankylosing spondylitis; Enteropathic arthritis; Psoriatic arthritis; Reactive arthritis; Seronegative spondyloarthropathy

Mesh:

Substances:

Year:  2018        PMID: 29759124     DOI: 10.1016/j.pop.2018.02.005

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  4 in total

1.  Vertebral Related Diseases in Healthcare: The Role of Pain Management and Rehabilitation.

Authors:  Alessandro de Sire; Nicola Marotta; Antonio Ammendolia
Journal:  Healthcare (Basel)       Date:  2022-06-14

2.  Cardiac Manifestations of Seronegative Spondyloarthropathy in a Human Leukocyte Antigen B27-Positive African American Woman: A Case Report With Literature Review.

Authors:  Olisaemeka Achike; Adeyemi Taiwo; Rajasekhar Nekkanti; Constantin Bogdan Marcu
Journal:  CASE (Phila)       Date:  2019-06-12

3.  Early instauration granulomatous pneumonitis associated with use of etanercept in seronegative spondyloarthropathy: Case report.

Authors:  Liliana Fernández-Trujillo; María B Iriarte; Germán Puerta; Eliana I Morales; Luz F Sua; Carlos A Cañas
Journal:  Respir Med Case Rep       Date:  2020-05-18

Review 4.  Emerging story of gut dysbiosis in spondyloarthropathy: From gastrointestinal inflammation to spondyloarthritis.

Authors:  Xing Lyu; Jieli Chen; Xingjie Gao; Jie Yang
Journal:  Front Cell Infect Microbiol       Date:  2022-08-22       Impact factor: 6.073

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.